The FDA approval is approaching. But these five problems might outlive it.
Hundreds of people gathered yesterday, in person and virtually, at the FDA's White Oak campus for a four-hour hearing on the therapeutic use of psychedelics. About eighty speakers delivered two-minute comments. For the most part, those comments covered provider training, risk mitigation programs, and the conditions of administration: whether psychotherapy should be required, how restrictive a REMS should be, whether treatment must occur inside a clinic. These are important questions, but there remain other questions that will limit what this class of drugs can ultimately achieve if they remain unaddressed.
1. Are We Measuring the Right Thing?
Psychedelics were developed for depression, and so they were evaluated with the instruments built for antidepressants: behavioral despair assays in preclinical work, depression rating scales in the clinic. Those instruments are appropriate for depression. But depression is largely a disorder of drive, a loss of impetus. Psychedelics appear to act elsewhere: on how a patient relates to their own narrative, their sense of meaning, their sense of self. Instruments exist for that dimension, for example the demoralization scales. Continuing to measure this class with the wrong instrument means continuing to underestimate it, at a cost to patients and to the companies developing these compounds.
2. Are We Measuring at the Right Resolution?
Even with an appropriate scale, a second problem remains. Approval is granted by diagnosis, but a diagnosis is a composite. Two patients carrying the same diagnosis may have different underlying deficits. For example, anhedonia is present in some depressed patients and absent in others. If a psychedelic acts powerfully on anhedonia and the trial enrolls everyone who meets the depression diagnosis, the patients without that deficit will dilute the signal. A strong effect is then concealed within a weak average. Enrolling patients who carry the relevant deficit is how the field learns what these drugs actually do, and for whom.
3. Who Will Own This Class of Medicine?
As capital has entered, the field has become heavily patented. Not on psilocybin itself, which is a natural compound, but on specific crystalline forms of it, defined within narrow tolerances. In several states, legislation has been drafted naming one particular crystalline form, which in practice names a single company's product. Therefore, the room to develop alternatives is shrinking. Patented formulations reach patients first while comparable or superior molecules remain shelved. Generic entry is a decade or more away, and follow-on patents continue to be filed. This is a substantive barrier to affordable and equitable access.
4. Who Gets Paid, and Who Gets Left Out?
There are legitimate chemical routes around an existing patent: deuteration, isomer discovery, prodrug design through esterification. This is valuable work, and it is how the field arrives at the optimal version of a compound. But it also invites patent trolling, in which the territory around the significant molecules becomes so crowded and so unclear that development stalls. Organizations such as Porta Sophia counter this by documenting prior art, including traditional and oral knowledge, so that weak patents are not granted in the first place.
That prior art points to a question the field has largely set aside. The communities who first identified these medicines, largely indigenous, are absent from the economics built on top of them. Their knowledge is invoked freely as a source of legitimacy and admitted nowhere as a claim. A royalty pool, a bounty for contributed prior art, or direct funding are all viable mechanisms for correcting that.
5. Who Actually Gets Treated?
Access was a dominant theme at yesterday's hearing, but the discussion concentrated almost entirely on how restrictive the program should be and where treatment may occur. That is a supply-side conversation. It leaves untouched what happens on the demand side once supply is constrained, which is that the queue sorts itself by ability to pay.
There is a meaningful distinction between a patient who requires this treatment and a person who would like it. Treatment-resistant depression, post-traumatic stress, addiction: that is need. A desire for perspective or personal development: that is preference. Both may be legitimate, but only one will be reimbursed, and reimbursement follows the label. The person who wants treatment can pay out of pocket immediately. The patient who needs it waits on a payer.
Access policy should be built now, before the pattern consolidates, so that clinical severity determines priority rather than ability to pay. The alternative is that psychedelics establish themselves as a wellness product first, with clinical treatment as a secondary channel, rather than the other way around.